Om

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders. Polaryx Therapeutics works on small molecule and gene therapy programs designed to address the underlying biology of severe inherited conditions, including neuronal ceroid lipofuscinoses, Krabbe disease, Tay-Sachs and Sandhoff diseases, and Niemann-Pick disease types A and B. Its current portfolio emphasizes patient-friendly treatment approaches, including orally available small molecules and a gene therapy candidate, supporting its role in the rare disease drug development market. Headquartered in Paramus, New Jersey, and founded in 2014, Polaryx Therapeutics is positioned as a specialized biotechnology company addressing areas of high unmet medical need.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I POLARYX THERAPEUTICS MED ENDAVU: Køb Polaryx Therapeutics ($1V8) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Polaryx Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.